Cedazuridine E7727|cas:1141397-80-9|西域试剂

Cedazuridine E7727,98.0%

产品编号：Bellancom-109081| CAS NO：1141397-80-9| 分子式：C₉H₁₄F₂N₂O₅| 分子量：268.21

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-109081	￥2700.00	杭州北京（现货）
Bellancom-109081	￥4300.00	杭州北京（现货）
Bellancom-109081	￥7500.00	杭州北京（现货）
Bellancom-109081	￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cedazuridine E7727

产品介绍

Cedazuridine (E7727) (Compound 7a) 是一种具有口服活性的胞苷脱氨酶 (CDA) 抑制剂，其 IC₅₀ 值为 0.4 μM。Cedazuridine 可用于癌症的研究。

生物活性

Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC₅₀ value of 0.4 μM. Cedazuridine can be used for cancer research.

体外研究

Cedazuridine (Compound 7a) exhibits superior acid stability.
Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models
Dosage:	3 mg/kg
Administration:	Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:	Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.

Animal Model:	NSGS male mice
Dosage:	1, 3, 10 and 30 mg/kg
Administration:	Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:	Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.

体内研究

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models
Dosage:	3 mg/kg
Administration:	Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:	Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.

Animal Model:	NSGS male mice
Dosage:	1, 3, 10 and 30 mg/kg
Administration:	Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:	Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (186.42 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7284 mL	18.6421 mL	37.2842 mL
5 mM	0.7457 mL	3.7284 mL	7.4568 mL
10 mM	0.3728 mL	1.8642 mL	3.7284 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献